{
    "clinical_study": {
        "@rank": "8109", 
        "arm_group": {
            "arm_group_label": "[^14C]-LY2157299", 
            "arm_group_type": "Experimental", 
            "description": "Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug"
        }, 
        "brief_summary": {
            "textblock": "This study involves a single dose of 150 milligram (mg) of radiolabeled LY2157299\n      monohydrate in healthy participants. The study will determine how the body eliminates the\n      radioactivity and LY2157299 monohydrate.  Participants must be healthy surgically sterile or\n      postmenopausal females, or sterile males.  This study is approximately 8 to 15 days."
        }, 
        "brief_title": "A Study of LY2157299 Monohydrate in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy surgically sterile females, postmenopausal females, or sterile males\n\n          -  Body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2)\n\n          -  Have venous access sufficient to allow for blood sampling\n\n        Exclusion Criteria:\n\n          -  Have known allergies to LY2157299, related compounds or any components of the\n             formulation\n\n          -  Have an abnormal blood pressure as determined by the investigator\n\n          -  Have participated in a [^14C]-study within the last 6 months prior to admission for\n             this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746004", 
            "org_study_id": "14671", 
            "secondary_id": "H9H-MC-JBAM"
        }, 
        "intervention": {
            "arm_group_label": "[^14C]-LY2157299", 
            "description": "[^14C]-LY2157299 monohydrate administered as oral solution", 
            "intervention_name": "[^14C]-LY2157299", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Disposition of [14C]-LY2157299 Monohydrate Following Oral Administration in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Urinary and Fecal Excretion of LY2157299 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose through Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Maximum Observed Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Day 14"
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Time of Maximum Observed Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Day 14"
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of LY2157299 and Radioactivity Area Under the Concentration-Time Curve from Time Zero to the Last Timepoint with a Measurable Concentration (AUC 0 to tlast)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Day 14"
            }, 
            {
                "measure": "Relative Abundance of LY2157299 and the Metabolites of LY2157299 in Urine and Feces", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Day 14"
            }, 
            {
                "measure": "Relative Abundance of LY2157299 and the Metabolites of LY2157299 in Plasma", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Day 14"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}